Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02624570
Title Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy.
Recruitment No longer available
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals

acute myeloid leukemia



Age Groups: adult
Covered Countries USA

Additional content available in CKB BOOST